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ABSTRACT
Neglected tropical diseases (NTDs) are those affecting vulnerable people and causing 
additional social and economic burden. The aim of this study was to carry out a general 
overview of the health economic assessments involving the diagnosis and treatment of six 
NTDs: cutaneous leishmaniasis (CL), Chagas disease, cysticercosis, filariasis, schistosomiasis 
and visceral leishmaniasis (VL). The literature search was based on two of the main medical 
literature databases (Medline and SciELO) and identified 46 studies. Twenty-six studies 
(57%) addressed therapeutic strategies, while other 20 (43%) assessed diagnostic or both 
diagnostic and therapeutic approaches. The studies were published between 1994 and 2021, 
and 57% of them (26/46) were carried out in four countries. Cost-effectiveness analyses were 
conducted in 59% (27/46) of the studies. Economic studies of NTDs have timidly increased 
in recent years. Despite the improvement of analytical methods, completeness and accuracy 
of information, there are few new technologies applied to NTDs and public health systems. In 
addition, economic studies for NTDs are concentrated in a few countries. Thus, this review 
points out the need for investment in research, development and training of human resources 
dedicated to the economic analysis in health, especially on NTDs, as a strategy to reduce 
inequalities by optimizing the use of health resources. 
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INTRODUCTION
Neglected tropical diseases (NTDs) are diseases of poor, vulnerable, and 
voiceless people, living in remote, rural areas, urban slums or conflict zones in 
the developing world. These diseases include leishmaniasis, Chagas disease, 
cysticercosis/taeniasis, lymphatic filariasis, schistosomiasis, Buruli ulcers, dengue 
fever, dracunculiasis, echinococcosis, food-borne trematodiasis, human African 
trypanosomiasis, leprosy, onchocerciasis, rabies, soil-transmitted helminthiasis, 
trachoma, and yaws1. 
This diverse group of diseases prevails in tropical and subtropical regions of 
149 countries, affecting more than one billion people and costing billions of dollars 
every year. Predominantly in Africa, Asia and the Americas, these NTDs affect some of 
the world’s poorest and most marginalized communities1. These diseases cause death 
and disability and present growing challenges to health security and human progress. 
The social and economic burden of NTDs are explained by physical disabilities, 
including blindness and disfigurement, social stigma, discrimination, loss of social 
status, growth failure, malnutrition and impaired cognitive development2.
Considering the socioeconomic complexity involved, an approach to reduce 
the burden of NTDs should necessarily include multilevel interventions. Control 
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programs including transmission interruption, access to 
diagnosis, mass drug administration and surveillance 
systems are some of them3. The lack of diagnostic tests 
and drugs that are affordable and cost effective are key 
contributing factors that cause high mortality and disability, 
thereby imposing a huge burden with severe social and 
economic consequences4.
Economic evaluations are still scarce for NTDs, and 
this is an alarming fact, considering that the most prevalent 
regions for these diseases are those that can least afford 
them. In general, a full health economic evaluation is 
defined as the comparative analysis of alternative courses 
of action in terms of costs and consequences5.
Partial evaluations only address one aspect of a single 
intervention, such as cost. Cost minimization analysis 
refers to the simple comparison of cost between two 
interventions with equivalent clinical consequences. Cost-
effectiveness analysis refers to the evaluation of the costs 
and consequences of interventions using clinical outcomes 
in natural units, such as complications avoided or cases 
diagnosed. These outcomes should be expressed as the 
“incremental cost-effectiveness ratio” (ICER), calculated 
by dividing the incremental cost of the new intervention by 
the incremental change in effectiveness6,7.
Cost-utility analysis is a subtype of cost-effectiveness 
analysis that focuses on measuring the patient’s preference 
for being in a particular health-state. The outcome is most 
commonly reported as the cost per quality-adjusted life 
year (QALY) or disability adjusted life year (DALY). 
Cost-benefit analysis measures consequences in monetary 
terms. Budget impact analysis complements the analyses 
mentioned above. It assesses the affordability of a new 
intervention with the resource constraints of a specific 
healthcare setting6,8.
Supporting an efficient resource allocation process with 
health economic evidence is urgent, as poor populations are 
vulnerable to a wide spectrum of diseases and are assisted by 
budget-scarce health systems8. Health economic evaluations 
can potentially provide valuable information to clinicians 
and policy makers regarding the financial implications 
of decisions about the care of patients. New needs and 
technological solutions applied to health fields increase in 
proportion to the population growth, as the result of science 
progress and improvement of general expectations about 
healthcare and quality of life. At the same time, budgetary 
and human resource constraints impose complex decisions 
for health managers. In this context, economic assessments 
emerge as useful tools to strengthen decision-making and 
support public policies. This manuscript reviews health 
economic assessments for the diagnosis and treatment of 
six NTDs.
MATERIALS AND METHODS
Six NTDs are selected as of interest in this study, 
namely: cutaneous leishmaniasis (CL), Chagas diseases, 
cysticercosis, filariasis, schistosomiasis and visceral 
leishmaniasis (VL). A search was carried out in two of 
the largest databases in the health field: Medline by US 
National Library Medicine and the Brazilian SciELO 
(Scientific Electronic Library Online). As a strategy 
for a comprehensive and, at the same time, focused 
search on the topic of interest, MeSH (Medical Subject 
Headings) terms combinations using the name of each 
one of the six neglected diseases and the terms “cost” 
or “cost effectiveness” combined by Boolean operators 
was used. Partial or complete economic assessments, 
published in the English, Spain and Portuguese languages 
were included, with no restriction on data of publication. 
Studies addressing animals and vectors were excluded. The 
title, abstract and keywords of every retrieved study were 
revised independently by two researchers and discrepancies 
have been resolved by discussion and consensus. Studies 
retrieved in duplicate by the two databases were removed. 
A Flow diagram of the study selection process is available 
in Supplementary Material (Figure S1). The quality of 
the studies included in the present narrative review was 
analyzed according to the Consolidated Health Economic 




Cutaneous leishmaniasis ("Leishmaniasis"[Mesh]) AND "Cost-Benefit Analysis"[Mesh] Leishmaniasis AND Costs 
Chagas disease ("Chagas Disease"[Mesh]) AND "Cost-Benefit Analysis"[Mesh]) Chagas Disease AND Cost
Cysticercosis ("Cysticercosis"[Mesh]) AND "Cost-Benefit Analysis"[Mesh]) Cysticercosis AND Cost
Filariasis ("Filariasis"[Mesh]) AND "Cost-Benefit Analysis"[Mesh] Filariasis AND Cost 
Schistosomiasis
("Schistosomiasis mansoni"[Mesh]) AND "Cost-Benefit 
Analysis"[Mesh])
Schistosomiasis mansoni AND Cost
Visceral leishmaniasis ("Leishmaniasis"[Mesh]) AND "Cost-Benefit Analysis"[Mesh] Leishmaniasis AND Cost
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Evaluation Reporting Standards (CHEERS) statement9, a 
checklist with recommendations on the minimum amount 
of information to be included when reporting economic 
evaluations. 
RESULTS
The search strategy identified 316 publications and after 
screening, 46 of them were included in this review: 10 for 
CL, nine for Chagas disease, two for cysticercosis, five for 
filariasis, five for schistosomiasis and 15 for VL. Twenty-six 
studies (57%) addressed therapeutic strategies, and 20 
(43%) studies addressed diagnostic or both diagnostic and 
therapeutic strategies (Table 2). 
The studies were published between 1994 and 2021 
(Figure 1); 57% of them (26/46) were performed in four 
countries: Brazil, India, Colombia and Mexico (Figure 2). 
Cost-effectiveness analyses were conducted in 59% (27/46) 
of the studies, cost estimates in 37% (17/46), cost-benefit 
analyses in 2% (1/46) and budget impact analyses in 2% 
(1/46) (Figure 3). 
Below are the details of the main results presented in 
the 46 studies included in this narrative review.
Cutaneous leishmaniasis
Economic analysis of treatment
In Afghanistan, Reithinger and Coleman10 calculated 
the cost effectiveness of intralesional and intramuscular 
administration of sodium stibogluconate for the treatment of 
CL patients attending clinics in a complex emergency setting. 
The cost per DALY averted was estimated to be US$1,200 
per patient treated and cured, showing that the treatment of 
CL in that country is not a cost-effective health intervention 
according to the WHO-CHOICE criteria. Stahl et al.11 
estimated the cost effectiveness of two wound care regimens 
for CL in three groups: I - intralesional infiltration of sodium 
stibogluconate; II - wound debridement with high-frequency 
Table 2 - Economic studies addressing diagnostic, diagnostic and therapeutic or therapeutic strategies for neglected tropical diseases. 
Disease Retrieved studies Included studies
Included studies 






Cutaneous leishmaniasis 70 10 0 10
Chagas disease 80 9 8 1
Cysticercosis 21 2 1 1
Filariasis 52 5 1 4
Schistosomiasis 20 5 3 2
Visceral leishmaniasis 70 15 7 8
Total 313 46 20 26
Figure 1 - Number of economic analyses for the diagnosis and treatment of neglected tropical diseases published per year.
Machado de Assis et al.
Rev Inst Med Trop São Paulo. 2021;63:e41Page 4 of 14
electrothermo-debridement with subsequent moist wound 
treatment with DAC N-055; or III - moist wound treatment 
in patients with a single chronic CL ulcer with DAC N-055. 
The mean costs per patient and the effectiveness in wound-
free days in groups I, II and III were US$11.43 and 129; 
US$15.91 and 177; US$24.97 and 147, respectively. The 
ICER of group II × I was US$0.09, and of group III × I was 
US$0.77, which is very cost effective. The authors concluded 
that wound debridement with high-frequency electrothermo-
debridement with subsequent moist wound treatment with 
DAC N-055 was the most cost-effective treatment.
In Colombia, Vega et al.12 estimated the cost per DALY 
averted in the treatment of CL in Chaparral. The costs of 
treatment with pentavalent antimony (Glucantime) per 
patient treated and cured and per DALY averted were 
estimated to be US$345 and US$15.000, respectively. The 
authors highlighted that according to the WHO-CHOICE 
criteria, treatment in Chaparral is not a cost-effective 
health intervention and may not even be justifiable from an 
economic point of view. Cardona-Arias et al.13 compared 
the cost effectiveness of thermotherapy and pentavalent 
antimonial for the treatment of CL. The thermotherapy 
Figure 2 - Number of economic analyses for the diagnosis and treatment of neglected tropical diseases per country.
Figure 3 - Type of economic analysis performed.
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showed average cost-effectiveness ratios ranging between 
$187 and $390, and Glucantime between $721 and $1,275. 
The authors pointed out that the excellent cost-effectiveness 
ratio observed for thermotherapy is a key feature for 
guiding decisions in the CL management in Colombia. In 
another study, the same authors estimated that the cost of 
thermotherapy would be US$2062 per DALY averted and 
US$69 per patient cured, and with pentavalent antimony 
(Glucantime), the cost would be US$4241 per DALY 
averted and US$85 per patient cured. The authors concluded 
that thermotherapy was a cost-effective strategy for the 
management of CL in Colombia, and this evidence adds 
to previous findings that have demonstrated the multiple 
benefits of this alternative treatment, such as better patient 
compliance, the simplicity of application, safety, and low 
costs14. Berger et al.15 performed a cost-effectiveness 
analysis comparing meglumine antimoniate and miltefosine 
administered by caregivers’ directly observed therapy 
(cDOT) for CL among children. The mean cost-per-cure by 
patient, government and social perspective for meglumine 
antimoniate and miltefosine were as follows: $442 and $30; 
$89 and $158; $531 and $188, respectively. The treatment 
of CL with miltefosine via cDOT showed cost savings from 
patients and social perspectives and was moderately more 
expensive from the government payer perspective. The 
authors highlighted that the development of such treatment 
programs represents an important opportunity to improve 
treatment and outcomes of pediatric CL patients. 
In Brazil, Mistro et al.16 compared the cost effectiveness 
of liposomal amphotericin B, pentavalent antimony 
and amphotericin B deoxycholate for the treatment of 
mucocutaneous leishmaniasis from the perspectives of 
the hospital and public health managers. After 12 months 
of treatment, pentavalent antimony showed mean costs of 
US$3,782.38, amphotericin B deoxycholate of US$5,211.27 
and liposomal amphotericin B of US$11,337.44. The cure 
rate of patients with liposomal amphotericin B was 100%, 
with amphotericin B deoxycholate was 77.4%, and with 
pentavalent antimony was 72.2%. Regarding the outcome 
of therapeutic success, liposomal amphotericin B had 
an ICER of US$18,816.23 compared with pentavalent 
antimony amphotericin B deoxycholate (US$24.504,65). 
In this study, liposomal amphotericin B was cost effective 
when used as the first-line therapy for the treatment of 
mucocutaneous leishmaniasis. The authors suggest that this 
result encourages the negotiation of costs to aquire the drug 
and the mean price that the health system will be willing to 
pay for each patient treated. 
Brito et al.17 estimated the cost effectiveness of 
meglumine antimoniate intralesional infiltration (IL) 
compared to endovenous (IV) meglumine antimoniate 
therapy for the treatment of CL; the strategies had a total 
cost per patient cured of US$330.81 (IL) and US$494.16 
(IV), respectively. The ICER showed that the intralesional 
meglumine antimoniate approach could result in savings of 
US$864.37 for each additional patient cured, confirming 
that the IL meglumine antimoniate strategy is cost effective 
in the context of the Brazilian public health scenario.
Galvão et al.18 evaluated direct medical and non-medical 
costs related to CL treatment in a Brazilian referral center. 
One hundred patients were included; 50% had a monthly 
per capita income of up to USD 259.60 and spent on average 
USD 187.32 with the disease, representing an average 
monthly impact of 22.5% (USD 133.80). The disease 
imposed direct medical costs and although the Brazilian 
public health system guarantees access to health care, CL 
still represents a substantial economic impact.
Carvalho et al.19 estimated the direct medical costs of the 
treatment for mucosal leishmaniasis using three therapeutic 
approaches in the Brazilian context: meglumine antimoniate, 
liposomal amphotericin B, and miltefosine. Treatment with 
meglumine antimoniate had the lowest average cost per 
patient (US$ 167.66), followed by miltefosine (US$ 259.92) 
in the outpatient treatment regimen. On the other hand, the 
average cost of treatment with liposomal amphotericin B 
was US$ 715.35. These results showed marked differences 
in costs between the therapeutic alternatives for mucosal 
leishmaniasis. 
Chagas disease
Economic analysis on diagnosis, diagnosis and treatment 
or treatment
In the United States, Wilson et al.20 evaluated the 
cost effectiveness of the implementation of three testing 
strategies in blood banks: A) Trypanosoma cruzi serology 
for the screening of all blood donations - enzyme-linked 
immunosorbent assay (ELISA); B) verbal screening 
initiating with three questions and then continuing with 
serological testing only for those positive on the verbal 
screening; and C) no verbal screening or serology testing for 
Chagas disease at all. The authors concluded that the A and 
B strategies are highly cost-effective compared with the C 
strategy across a wide range of risk levels to Chagas disease. 
In Mexico, Agapova et al.21 estimated the cost 
effectiveness of seven testing strategies against no testing: 
1) risk question; 2) donations only; 3) donors for the first 
time and donors with repeated risks; 4) test everyone once 
and those with repeated risks; 5) test everyone twice and 
those with repeated risks; 6) test whole blood and PLT 
donations; and 7) universal testing. Compared with no 
testing, the cost effectiveness of testing all blood donors 
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once was $757,000 per QALY, testing all donors twice was 
$970,000 per QALY, and universal testing was $1.36 million 
per QALY. The authors highlighted that the selective 
screening provides approximately the same effectiveness 
as the universal screening, but with reduced costs. 
Ramsey et al.22 analyzed costs and impacts of the early 
treatment of Chagas disease using Markov’s decision model 
based on previous publications. The lifetime cost for a 
timely diagnosed and treated Chagas disease patient was 
estimated at US$ 10,160, while the cost for an undiagnosed 
individual was estimated at US$ 11,877. The authors 
concluded that it is cheaper to diagnose and treat chagasic 
patients early, instead of doing nothing.
Bartsch et al.23 evaluated the impact, costs, cost 
effectiveness and cost-benefit of identifying and treating 
patients with acute and indeterminate Chagas disease. In the 
acute stage, identifying and treating patients averted 0.5-5.4 
acute cases, 0.6-5.5 chronic cases, and 0.6-10.8 DALYs, 
saving $694-$7,419 from the third-party payer perspective 
and $6,976-$79,950 from a social perspective. In the 
indeterminate stage, treating patients averted 2.2-4.9 acute 
cases, 6.1-12.8 chronic cases, and 11.7-31.1 DALYs, 
saving $7,666-$21,938 and $90,530-$243,068 from the 
third-party payer and social perspectives, respectively. The 
authors concluded that treating Chagas cases in the acute 
and indeterminate stages result in cost savings.
Sánchez-Gonzalez et al.24 calculated the ICER for 
total compliance of current guidelines from both, Mexican 
primary healthcare and regular salaried workers’ health 
service institutions. ICER was US$ 383 life-years gained for 
the Secretary of Health, while the cost for an additional life-
year gained was US$ 463 for the Social Security Institute. 
The authors highlighted that due to incomplete compliance 
of Mexico’s national legislation during 2013 and 2014, 
15,162 T. cruzi infections were not confirmed and 2,347 
avoidable infections were not prevented. 
In Peru, Moya-Salazar et al.25 evaluated the impact of 
seroprevalence and indeterminate results on lost units and 
cost per donation. A total of 7,723 donations were evaluated 
and the total loss was of 49,750 US dollars. The authors 
concluded that the prevalence of indeterminate results was 
elevated, causing a great impact on economic losses to the 
Blood Bank and the Transfusion Therapy Department of the 
Hospital Central de la Policia Nacional del Peru in Lima.
In Spain, Sicuri et al.26 performed an economic 
evaluation of screening Chagas disease in pregnant 
women from Latin America and their newborns, against 
the alternative hypothesis of no screening of mothers and 
newborns. In any scenario, the screening option showed 
to be cost effective compared with no screening. In the 
newborns, the cost-effectiveness ratio of the strategy 
“test” was US$22/QALYs gained versus US$125/QALYs 
gained using the strategy “no test”. In the mothers, the 
cost-effectiveness ratio of the strategy “test” was US$96/
QALYs gained, and US$1675/QALYs gained in the “no 
test” strategy. The authors showed that the screening 
option proved to be cost effective against no screening 
and provided useful information in the decision-making 
process. Imaz-Iglesia et al.27 carried out a cost-utility 
analysis of several strategies for Chagas disease screening 
among Latin American residents living in Spain: 1) no 
screening; 2) screening of the Latin American pregnant 
women and their newborns; 3) screening extended to the 
relatives of positive pregnant women; 4) screening extended 
to the relatives of negative pregnant women. The authors 
concluded that no screening was the most expensive and 
least effective strategy evaluated, and among the evaluated 
screening strategies, the most efficient was to extend the 
antenatal screening of Latin American pregnant women 
and their newborns up to the relatives of positive women.
In Europe, Requena-Mendez et al.28 performed 
an economic evaluation of systematic Chagas disease 
screening of Latin American populations attending primary 
care centers. The modeling compared the option of the 
test performed (screening of asymptomatic individuals, 
treatment, and follow-up of positive cases) versus the no test 
option (screening, treating, and follow-up of symptomatic 
individuals). The total costs for the test and no test option 
were €32 163 649 and €6 904 764, respectively, and the 
QALYs gained were 64 (634,35) and 59 (875,73) in the 
probabilistic analysis, respectively. For a treatment efficacy 
of 20%, ICER was €6840,75 per QALY gained and for a 
treatment efficacy of 50%, it was €4243 per QALY gained. 
The authors highlighted that screening for Chagas disease 
in asymptomatic Latin American adults living in Europe is 
a cost-effective strategy.
Cysticercosis 
Economic analysis of diagnosis 
In India, the total cost of imaging studies of the brain 
was 8,180 Indian rupees ($1 is approximately 28 rupees), 
respectively. The authors highlighted that magnetic 
resonance imaging is far more specific in detecting and 
evaluating lesions than computed tomography scanning and 
that the risk of anaphylactic reactions and overall patient 
morbidity using this technique is also reduced29.
Economic analysis of treatment
In Mexico, Medina-Santillán et al.30 compared the 
cost of two therapeutic schemes of praziquantel for the 
treatment of neurocysticercosis: 1) conventional treatment 
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with praziquantel 50 mg/kg/day for 15 days; and 2) three 
doses of praziquantel 25 mg/kg per dose administered on 
the same day in a two-hours intervals. The total direct cost 
of conventional treatment was 2,073.28 pesos compared 
with 212.04 pesos for the one-day treatment. The authors 
concluded that the second scheme had a direct impact on 
costs, with a 90% reduction with respect to the traditional 
scheme, and with this short-scheme, hospitalization was 
unnecessary, and the costs of hospital visits for patient and 
family were avoided.
Filariasis
Economic analysis of diagnosis
In Sri Lanka, Chandrasena et al.31 estimated the cost 
effectiveness of an immunochromatographic card test (ICT) 
compared with two standard parasitological techniques: 
thick blood film (TBF) and nucleopore membrane filtration. 
In this study, ICT was more effective (sensitivity of 100% 
and specificity of 94%) than the parasitological techniques 
in diagnosing infection by lymphatic filariasis. The direct 
costs of the TBF and ICT were US$0.30 and US$2.75, 
respectively. The authors highlighted that although TBT 
is the standard survey tool in Sri Lanka, in a situation of 
lack of good laboratory facilities and trained staff, the ICT 
would be an alternative.
Economic analysis of treatment
In Tanzania, Michael et al.32 examined the cost 
effectiveness of four different mass diethylcarbamazine 
(DEC) chemotherapy regimens in reducing the microfilarial 
(mf) prevalence at the community level: I) regimens-
standard; II) semi-annual single dose; III) low monthly 
dose; and IV) DEC-medicated salt. The implementation 
cost of strategies I, II, III and IV was US$970,0; US$355,7; 
US$392,8 and US$1442,9, respectively, and the cost per 
case cured was US$25,5; US$5,2; US$5 and US$17,4, 
respectively. Strategy IV was the most effective in terms of 
reducing the prevalence of microfilaremia and has potential 
to be the predominant intervention. The authors reported 
that this strategy becomes significantly cost efficient only 
when the salt delivery mechanism is simplified.
In India, Krishnamoorthy et al.33 compared the cost 
effectiveness of mass drug administration alone versus 
mass drug administration associated with vector control. 
The cost for stopping an infective mosquito from biting a 
villager using mass drug administration alone was US$1.80 
compared with US$3.32 to achieve the same result using 
mass drug administration in addition to vector control. 
In 2010, Chu et al.34 analyzed the economic benefits of the 
Global Program to Eliminate Lymphatic Filariasis between 
2000-2007. During the first eight years of the program, an 
estimated US$21.8 billion of direct economic benefits were 
gained over the lifetime of 31.4 million individuals treated 
with albendazole, ivermectin, diethylcarbamazine. More 
than 28 million individuals already infected were benefited 
by the program, resulting in an associated lifetime economic 
benefit of US$19.5 billion, and the reduced morbidity saved 
the health systems of endemic countries approximately 
US$2.2 billion. The authors highlighted that the economic 
rate of return of the program is high and proves itself an 
excellent investment at the level of public health.
In 2017, Turner et al.35 evaluated the cost effectiveness 
and cost-benefit of the preventive chemotherapy provided 
under the Global Program to Eliminate Lymphatic Filariasis 
between 2000 and 2014 in addition to the potential cost 
effectiveness of hydrocele surgery. The authors concluded 
that the preventive chemotherapy and hydrocele surgeries 
were cost effective, defined as less than $246 per DALY 
averted, and represented a very good investment in public 
health.
Schistosomiasis
Economic analysis of diagnosis or diagnosis and treatment 
In Kenya, Worrell et al.36 compared the costs of a single 
stool Kato-Katz test, triplicate stool Kato-Katz tests, and 
point-of-contact circulating cathodic antigen assays (POC-
CCA) for the detection of Schistosoma mansoni; the unit 
cost of the diagnostic tests was US$6.89, US$17.54, and 
US$7.26, respectively. The authors suggested that the 
slightly higher cost of POC-CCA may be justified for its 
greater sensitivity to detect schistosomiasis. 
In Burundi, Carabin et al.37 evaluated the cost 
effectiveness of three alternative screening strategies in 
delivering treatment to patients with symptoms suggestive of 
S. mansoni: A) screening all symptomatic individuals using 
a Kato-Katz test and treating only positives; B) treating all 
symptomatic individuals; or C) treating only those with 
symptoms of severe diarrhea. In this study, the A strategy 
was more cost effective than treating all symptomatic 
patients, with cost-effectiveness ratios estimated at US$4.2 
and US$12.43 per infected person treated, respectively. 
The authors concluded that the sustainability of strategy 
B is closely related to the endemic level and the the price 
of the drug.
In Brazil, Nascimento et al.38 estimated the cost of 
schistosomiasis in 2015 from the social perspective. The 
study included 26,499 infected people, 397 hepatosplenic 
cases, 284 hospitalizations, 48 cases with the neurological 
form. The total cost of schistosomiasis was estimated to 
be US$ 41,7 million, including spending on diagnosis, 
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adverse events of treatment, transportation, patients’ care 
at home and premature death. The authors concluded that 
the economic burden of disease in Brazil is high. 
Economic analysis of treatment 
In Tanzania, Guyatt and Chan39 investigated the cost 
effectiveness of school-targeted treatment for S. mansoni. 
In this study, drugs with low efficacy produced high and 
variable cost-effectiveness ratios. The authors highlighted 
that the interactions between drug price and drug efficacy 
are complex and suggested that given the current price range 
of praziquantel, a drug with less than 50% effectiveness in 
killing the worms is not to be recommended.
In Egypt, Carabin et al.40 estimated the cost and 
effectiveness of reaching non-enrolled children through 
school-based programs: school-based (coverage of 85%) 
and school-aged targeted (coverage of 25, 50 and 85%) 
programs. Programs in which only 85% of children were 
treated would prevent 77% of the early disease cases. 
However, the authors pointed out that to use school-aged 
targeted strategy, raised from US$0.06 to US$1.03 the 
extraunitcosts and that the strategy could be designed 
to reach non-enrolled children and be even more cost 
effective. 
Visceral leishmaniasis 
Economic analysis of diagnosis or diagnosis and treatment
In Sudan, Boelaert et al.41 compared four strategies for 
treatment of VL suspects cases: 1) treatment of all suspects; 
2) parasitological tests followed by treatment of positives; 
3) two-step testing using the direct agglutination test (DAT) 
followed by treatment of patients with high titers as well 
as those with parasitological confirmed infections after a 
borderline DATresult ; or 4) DAT followed by treatment of 
positives with high titres. The strategy B was the most cost-
effective estimating US$448 per death averted. The authors 
suggested that the introduction of DAT in diagnostic-
therapeutic algorithms contributed to decision making and 
favored the effective use of resources allocated to control 
the disease. Boelaert et al.42 have also evaluated whether the 
potential improvements in chemotherapy would affect the 
choice of the ‘optimal’ test-treatment algorithm: Strategy A: 
treats all clinically suspect patients without testing, leading 
to either a correctly treated VL case or an erroneously 
treated non-VL case; Strategy B: relies on parasitological 
diagnosis in which only persons with positive parasitology 
are treated, leading either to a correctly treated VL case or an 
erroneously treated non-VL case; and Strategy C: serology 
(DAT) differs only from the former to the extent that a 
serological test is used instead of a parasitological one. The 
authors highlighted that strategy C is the best option and 
constituted the optimal choice. 
Vanlerberghe et al.43 compared the cost effectiveness 
of four drug regimens for VL associated with a serological 
rapid test: 1) amphotericin B deoxycholate (Amb-D); 2) 
pentavalent antimonial; 3) miltefosine; and 4) liposomal 
amphotericin B. Treatment with AmB-D was the most 
effective (349 deaths averted per 1000 clinical suspects) 
approach, and miltefosine was the most cost-effective 
approach (US$ 327.9 per death averted). The authors 
highlighted that miltefosine has the advantage of oral 
administration, but there is a disadvantage of the potential 
teratogenicity of this drug. Therefore, one of the challenges 
is to reduce the price of the drugs, mainly of liposomal 
amphotericin B. 
In Brazil, Machado de Assis et al.44 reported the process 
and costs of implementing two tests to decentralize the 
diagnosis of VL in an endemic city: a rapid test (IT LEISH) 
and a direct agglutination test (DAT-LPC). Estimation of 
the training costs considered the proportional remuneration 
of all professionals involved and the direct costs of the tests 
used for training. During November 2011 and November 
2013, 17 training sessions were held, and 175 professionals 
were trained. The training cost for each professional was 
US$ 7.13 for the IT LEISH and US$ 9.93 for the DAT-
LPC. The direct costs of the IT LEISH and DAT-LPC were 
estimated to be US$ 6.62 and US$ 5.44, respectively. This 
evaluation on the implementation of these diagnostic tests 
indicated the feasibility of decentralizing both methods to 
extend the access to VL diagnosis in the country. Machado 
de Assis et al.45 evaluated the cost effectiveness of six 
diagnostic options for VL: the rapid test IT LEISH, rapid 
test Kalazar Detect, DAT, indirect immunofluorescence 
antibody test (IFAT), polymerase chain reaction (PCR) 
and direct examination of bone marrow aspirate. In this 
study, DAT presented the lowest cost (US$4.92) and 
highest effectiveness (99%) per correctly diagnosed 
case. The authors suggested that these results highlight 
the need for a revision of the algorithm for VL diagnosis 
in Brazil. Replacements of IFAT with DAT-LPC are 
cost-effective public health measures. In an analysis of 
budgetary impact, Machado de Assis et al.46 estimated the 
financial costs of the incorporation and/or replacement of 
the six diagnostic tests evaluated previously. The costs to 
diagnose VL cases over three years using IFAT and DAT 
were estimated at US$280,979.91 and US$121,371.48, 
respectively. The analysis indicated that, compared with 
the use of IFAT, the incorporation of DAT would result in 
savings of US$159,608.43. With regard to the budgetary 
impact of rapid tests, the use of IT LEISH resulted in 
savings of US$21.708,72 over three years. Compared with 
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the parasitological examination, the diagnosis by PCR 
resulted in savings of US$3,125,068.92 over three years. In 
addition, the cost effectiveness of six diagnostic-therapeutic 
alternatives was analyzed: 1) IT LEISH and pentavalent 
antimonial; 2) IT LEISH and liposomal amphotericin B; 
3) IFAT and pentavalent antimonial; 4) IFAT and liposomal 
amphotericin B; 5) DAT and pentavalent antimonial; and 
6) DAT and liposomal amphotericin B. Machado de Assis 
et al.47 showed that IT LEISH and liposomal amphotericin 
B emerged as the best option, presenting lower costs 
(US$659.79) and higher effectiveness (62.95) per year of 
life gained. The authors showed that liposomal amphotericin 
B should be used as the first-line drug for VL in Brazil.
Economic analysis of treatment
In Bihar, India, Thakur et al.48 compared a daily 
(group A) and an alternate-day regimen of amphotericin B 
(group B) for the treatment of VL. The cost of drugs and 
intravenous administration was the same in groups A and B; 
however, the expenses of board and lodging of two relatives 
per patient was higher in group B (US$225 versus US$92 
in group A). The authors highlighted that a daily regimen 
of amphotericin B was as efficacious as the alternate day 
regimen, much more cost effective and should be adopted 
for the treatment of this condition.
Sundar et al.49 evaluated if the costs of treatment with 
liposomal amphotericin B could be reduced by using 
ultrashort courses. The final cost per patient of treatment 
using amphotericin B lipid complex given daily ranged 
between US$561-1010 and given on alternate days ranged 
between US$490-715. The authors emphasized that 
treatment using liposomal amphotericin B is indicated 
for VL patients who fail to respond to the antimony 
therapy. Sundar et al.50 tested standard amphotericin B 
deoxycholate mixed with a commercial fat emulsion as a 
short-course treatment. The cost of treatment per patient 
was estimated to be US$260, and the authors showed that 
the short-course treatment was cost effective for patients 
with VL. Olliaro et al.51 assessed the cost effectiveness 
of current monotherapies and combinations (liposomal 
amphotericin B; paromomycin; miltefosine) for treating 
VL. The cost of monotherapies per averted years of life lost 
(YLL) ranged from US$2 for paromomycin to US$20-22 
for liposomal amphotericin B and for combinations ranged 
from US$5-8 per YLL averted. The authors demonstrated 
that the combinations evaluated were more cost effective 
than most monotherapies and emphasized that cost 
equalization policies are important to encourage the use of 
certain treatments.
In the Indian subcontinent (India, Nepal and Bangladesh), 
Meheus et al.52 assessed the cost effectiveness of ten isolate 
and combined therapies for VL treatment. The combination 
miltefosine-paromomycin was the most cost-effective 
strategy (US$92 per death averted). The authors suggested 
that there are concerns about drug resistance and that, in 
this context, combination therapies should be considered.
In Brazil, Machado de Assis et al.53 estimated the 
direct costs of therapies recommended by the Ministry 
of Health. The estimated direct costs of treatment for an 
adult patient using pentavalent antimonial administered by 
intramuscular and intravenous routes were US$418.52 and 
US$669.40, respectively. The estimated cost of treatment 
with amphotericin B deoxycholate was US$1,522.70, while 
the costs of liposomal amphotericin B were US$659.79 
and US$11,559.15, considering the price subsidized by 
WHO and the market price, respectively. The authors 
emphasized that replacing N-methyl glucamine antimoniate 
by liposomal amphotericin B is economically feasible. 
Carvalho et al.54 estimated the Brazilian direct and 
indirect costs of VL in 2014. The total cost of disease 
was estimated US$ 14,190,701.50. The direct medical 
costs corresponded to US$ 1,873,681.96, and most of it 
was associated with hospitalization (40%). Productivity 
loss corresponded to US$ 11,421,683.37 for premature 
mortality and US$ 895,336.18 for work absence due to 
hospitalization. The authors concluded that VL represents 
an expensive problem for the public health system and the 
society. 
In another study, also considering the Brazilin scenario, 
Carvalho et al.55 estimated the cost effectiveness of three 
therapeutic options for the treatment of VL: 1) pentavalent 
antimonial, 2) liposomal amphotericin B and 3) a 
combination of liposomal amphotericin B and pentavalent 
antimonial. In this study, the second strategy proved to be 
cost effective for treating VL. The authors highlighted that 
the use of liposomal amphotericin B can improve the care 
offered to patients with VL in Brazil. 
Quality of the articles included 
Eighty percent (40/46) of the articles included in this 
narrative review presented at least 19 out 24 CHEERS 
items. The CHEERS item with the highest rate of missing 
data among those retrieved in studies refers to the choice 
of discount rate(s) used for costs and outcomes (item 9), 
presented in 20/46 (44%) studies (Supplementary Material, 
Figure S2).
DISCUSSION
The growth in health spending has become a major 
problem for developing countries. In this context, economic 
Machado de Assis et al.
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health assessments represent a valuable tool to support 
decision making, optimizing the benefits of a technology 
according to the local health needs and cost possibilities. In 
developing countries, where resources are scarce and health 
needs are expensive, these assessments are particularly 
important56.
In the present study, a small number of publications 
concentrated in a few countries addressing diagnosis 
and treatment strategies for NTDs were identified. This 
observation allowed some extrapolations related to the 
current scenario of evidence development: 1) there is little 
investment in research and development of new diagnostic 
tests and medicines for NTDs; 2) there is a lack of trained 
professionals to conduct economic assessments; and 3) there 
is a lack of political interest to carry out decision making 
based on economic evidence. 
Marinho et al.8 reviewed the economic evaluations for 
VL treatment and had already reached the same conclusions. 
On the other hand, the quality of analyses produced is 
generally adequate and is improving over time. Most of 
the selected studies carried out cost-effectiveness analyses, 
corresponding to complete economic assessments. 
Some general notions can be extracted from the 
economic analyses available to date for NTDs. Regarding 
CL, two of the main findings are the confirmation of 
cost effectiveness of liposomal amphotericin B for 
hospitalized patients with mucocutaneous leishmaniasis 
and of the meglumine antimoniate intralesional approach, 
both in the context of the Brazilian National Health 
System. As a direct implication, these results should 
support the acquisition of liposomal amphotericin B for 
mucocutaneous leishmaniasis16 and the implementation 
of an intralesional approach with meglumine antimoniate, 
as has already been done, for patients with localized CL 
in Brazil17. 
In the case of Chagas disease, the set of evidence 
consolidated by several studies advocates in favor of 
serological testing of donors in blood bank as well as in 
antenatal screening20-28 as cost-effective public health 
strategies. These results corroborate the resolution of the 
World Health Assembly, which recommends Chagas disease 
screening for pregnant women in non-endemic areas if they 
were born in disease-endemic areas, if they have lived for 
a long time in disease-endemic areas, or if they were born 
to mothers who lived in disease-endemic areas57.
Considering cysticercosis, studies addressing cost 
estimates for magnetic resonance imaging, computed 
tomography and different praziquantel therapeutic schemes 
were identified. For filariasis, an immunochromatographic 
card test31 and mass drug administrations32,33 were 
suggested as cost-effective strategies. In addition, a 
multicenter study assessing different diagnostic tools 
for bancroftian filariasis elimination showed that 
the immunochromatographic card test is relatively 
inexpensive, requires no laboratory equipment, has 
satisfactory sensitivity and specificity and can be processed 
in 10 minutes58. In this sense, a mass drug administration 
program to eliminate lymphatic filariasis was initiated in 
2000 in 55 endemic countries. After 13 years, the program 
resulted in a significant reduction in the burden of disease59 
and Srividya et al.60, reported disease elimination in 11 
of the 72 endemic countries, with enormous efforts on 
systematic planning and implementation of the strategy.
In respect to schistosomiasis, the treatment of positive 
cases was shown to be more cost effective than treating all 
symptomatic patients37. However, preventive chemotherapy 
for schistosomiasis is still a subject of debate. Several 
authors emphasized the need for a better tailoring of 
preventive chemotherapy to the local environment in 
endemic areas and to emphasize the use of other measures 
in addition to chemotherapy61.
Concerning VL diagnosis, based on data mainly from 
Brazil and Africa, DAT and immunochromatographic 
rapid tests were identified as cost-effective strategies for 
diagnosing the disease44,46. Corroborating these findings, 
a recent validation of DAT and rapid test in Spain has also 
shown an acceptable sensitivity and specificity of these 
methods62. Regarding treatment, liposomal amphotericin 
B was confirmed as a cost-effective option for VL47,55.
In the present study, the quality of information available 
in the primary studies was assessed considering the 
CHEERS checklist9. Most studies (40/46) presented clear 
and complete information about the economic assessment 
performed. In this evaluation, the item 9 of CHEERS was 
the least scored and this result can be related to the fact that 
most studies have estimated cost and effectiveness at the 
present time and in the same year, thus not requiring the 
application of discount rates. 
Decimoni et al.63 have also evaluated the number, 
characteristics, and quality of reporting of published 
economic studies in a Brazilian setting between January 
1980 and December 2013. In total, 535 studies were 
included in the review, and overall, the quality of reporting 
was satisfactory and has increased progressively over time; 
however, some items were generally poorly reported. 
The authors pointed out that the following items need 
improvement: reporting of funding source, conflict of 
interest, methods for the estimation of resources quantities 
and unit costs, methods and source of evidence to estimate 
utility parameters. These deficiencies may be related to 
a lack of trained professionals to conduct the economic 
assessments mentioned above.
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CONCLUSION
In summary, this review confirms the scarcity of new 
health technologies being economically evaluated for 
NTDs. Given the existence of many unresolved issues and 
scientific but mainly financial obstacles related to access 
the nature of the NTD approach task, this observation 
deserves not only reflection but also a coordinated action. 
Particularly for countries with insufficient health budgets, 
economic analyses should be seen as essential tools for the 
rational allocation of resources. As a final message, our 
observations must serve as a warning to managers and health 
organizations with global influence on the need to create 
investment convergence strategies for diseases related to 
poverty, without which this reality can hardly be overcome.
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SUPPLEMENTARY MATERIAL
Figure S2 - Adequacy of the 46 articles included in the present narrative review to the 24 itens of Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) statement.
Figure S1 - Flow diagram of the study selection process.
